

Table S4. Pearson correlation, r, between pravastatin AUC with each of the biomarkers after administration with CSA. Figure 4 showed the correlation between pravastatin and each of the biomarkers.

(i) Including all genotype group of SLCO1B1 c.521T>C				
AUC_{last} (N=32)	HDA	TDA	CP-I	CP-III
Pearson, r (95% CI)	0.50 (0.18 to 0.72)	0.52 (0.21 to 0.73)	0.39 (0.047 to 0.65)	0.41 (0.070 to 0.66)
P-value	0.0038	0.0024	0.028	0.020
C_{max} (N=32)	HDA	TDA	CP-I	CP-III
Pearson, r (95% CI)	0.37 (0.020 to 0.63)	0.35 (0.00024 to 0.62)	0.16 (-0.20 to 0.48)	0.49 (0.17 to 0.72)
P-value	0.039	0.050	0.38	0.0043
(ii) Including individual with TT and TC genotype for SLCO1B1 c.521T>C				
AUC_{last} (N=28)	HDA	TDA	CP-I	CP-III
Pearson, r (95% CI)	0.56 (0.23 to 0.77)	0.75 (0.53 to 0.88)	0.32 (-0.064 to 0.62)	0.38 (0.014 to 0.66)
P-value	0.0021	<0.0001	0.10	0.043
C_{max} (N=28)	HDA	TDA	CP-I	CP-III
Pearson, r (95% CI)	0.49 (0.14 to 0.73)	0.66 (0.37 to 0.83)	0.17 (-0.21 to 0.51)	0.48 (0.12 to 0.72)
P-value	0.0084	0.0002	0.37	0.011